Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a …

LUMOXITI is a CD22-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies,...

2022年10月20日 · Lumoxiti是一种靶向CD22的抗体药物偶联物，也是全球首个获批用于治疗HCL的ADC。 系由一种重组鼠源IgG1抗体moxetumomab，通过可切割连接子与pasudotox融合而成。

Lumoxiti® (Moxetumomab pasudotox) Lumoxiti于2018年9月获得FDA批准上市，适用于复发或难治性毛细胞白血病（HCL）的成年患者。HCL是一种罕见的慢性血液病，可导致骨髓生成过多的异常B细胞，从而阻止健康血细胞的…

2018年9月14日 · Lumoxiti (moxetumomab pasudotox, formerly CAT8015 or HA22) is a CD22-directed cytotoxin and a first-in-class treatment in the US for adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

2021年2月13日 · Lumoxiti是一种抗CD-22重组免疫毒素，该药是治疗HCL的一种首创（first-in-class）级别的创新药物。 2018年10月，法国制药公司Innate Pharma SA与阿斯利康达成扩展合作协议，相互促进 肿瘤 学管线新药的开发。 根据合作协议条款，Innate Pharma将代理Lumoxiti在美国和欧盟市场的销售。 但在2020年12月11日，Innate Pharma SA宣布，将把Lumoxiti在美国和欧盟的商业化权利返还给阿斯利康。 2家公司将制定一个过渡计划，目标是在2021年将全部商业 …

2024年8月22日 · Lumoxiti is an injection used to treat hairy cell leukemia. Lumoxiti is used in adult patients with hairy cell leukemia that has relapsed. Lumoxiti is also used if the patient has not responded to previous treatments, and has received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA).

2020年9月3日 · LUMOXITI is a prescription medicine used to treat adults with hairy cell leukemia (HCL) that has come back or has not responded to previous treatment, and ; have received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA). It is not known if LUMOXITI is safe and effective in children.

奥加伊妥珠单抗是辉瑞和Celltech开发的一款抗体偶联药物 (ADC)，由靶向 CD22 的单克隆抗体与细胞毒制剂刺孢霉素偶联而成。 2017年奥加伊妥珠单抗先后在欧盟和FDA获批上市（BESPONSA® inotuzumab ozogamicin），用于治疗复发性或难治性前体B细胞急性淋巴细胞白血病。 在国内，2021年奥加伊妥珠单抗获NMPA批准上市（贝博萨® 奥加伊妥珠单抗），用于治疗复发性或难治性前体B细胞急性淋巴细胞白血病（ALL）的成年患者。 Moxetumomab …

Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888.